GlassScriptPhysician profile
Arun Reddy Mannem
NPI 1871721019
$5,653.73
in general payments reported to CMS, 2019-2025
32 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $319 · 2021: $347 · 2022: $492 · 2023: $927 · 2024: $1,060 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,738.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,836.10 | 2019-2025 | |
| Janssen Biotech, INC. | $552.89 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.61 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $349.33 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $255.78 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $252.16 | 2019-2025 | Entyvio |
| Pfizer INC. | $238.93 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $189.58 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $187.97 | 2019-2025 | |
| Enterra Medical, INC. | $186.90 | 2025 | |
| Genzyme Corporation | $171.54 | 2023-2025 | |
| Daiichi Sankyo INC. | $127.22 | 2019-2023 | Injectafer |
| Braintree Laboratories, INC. | $92.77 | 2019-2023 | Sutab, Suflave |
| Medtronic, INC. | $82.13 | 2025 | Gi Genius |
| Merck Sharp & Dohme LLC | $81.89 | 2019-2023 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $76.64 | 2024 | Iqirvo, Bylvay |
| Qol Medical, LLC | $73.44 | 2024-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $57.01 | 2021-2023 | |
| Celltrion USA INC. | $55.01 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $46.40 | 2025 | Rezdiffra |
| Novo Nordisk INC | $37.17 | 2019-2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $30.18 | 2019 | |
| Ucb, INC. | $25.05 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.97 | 2025 | Rebyota |
| Aimmune Therapeutics, INC. | $21.22 | 2025 | Zenpep |
| Mirum Pharmaceuticals, INC. | $19.15 | 2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $18.44 | 2019 | |
| Sandoz INC. | $18.18 | 2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.35 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $15.20 | 2023 | Voquezna |
| Mallinckrodt Hospital Products INC. | $15.03 | 2023 | Terlivaz |
| Allergan, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Mannem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.